The Lions have their second-straight, standalone national TV showcase this week. This time, it's on Monday night against the ...
T-DXd significantly improved IDFS and reduced the risk of invasive disease or death by 53% compared to T-DM1 in high-risk, HER2-positive breast cancer patients. The trial demonstrated superior ...
Tarlatamab combined with chemoimmunotherapy achieved a 71% objective response rate in ES-SCLC, with a median response duration of 11 months. The safety profile was manageable, with grade 3 or 4 ...
First graders at Northwestern State University Elementary Lab School showcased their knowledge of seeds and plant growth ...